These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21911300)

  • 1. Clinical programs in the development of similar biotherapeutic products: rationale and general principles.
    Berghout A
    Biologicals; 2011 Sep; 39(5):293-6. PubMed ID: 21911300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic products.
    Schiestl M
    Biologicals; 2011 Sep; 39(5):297-9. PubMed ID: 21784654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of the diverse situation of similar biotherapeutic products in the selected countries (August 2010).
    Kang HN
    Biologicals; 2011 Sep; 39(5):304-7. PubMed ID: 21880507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches.
    Fletcher MP
    Biologicals; 2011 Sep; 39(5):270-7. PubMed ID: 21875812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation.
    Knezevic I
    Biologicals; 2011 Sep; 39(5):256-61. PubMed ID: 21907589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory guideline for biosimilar products in Korea.
    Suh SK; Park Y
    Biologicals; 2011 Sep; 39(5):336-8. PubMed ID: 21784653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience of reviewing the follow-on biologics including Somatropin and erythropoietin in Japan.
    Arato T; Yamaguchi T
    Biologicals; 2011 Sep; 39(5):289-92. PubMed ID: 21917473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. China's perspective on similar biotherapeutic products.
    Liang C; Wang J
    Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
    Looper YJ
    Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 16. WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24-26 August, 2010.
    Wadhwa M; Kang HN; Knezevic I; Thorpe R; Griffiths E
    Biologicals; 2011 Sep; 39(5):349-57. PubMed ID: 21906959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The regulatory framework for similar biotherapeutic products in Cuba.
    Hechavarría Núñez Y; Pérez Massipe RO; Orta Hernández SD; Muñoz LM; Jacobo Casanueva OL; Pérez Rodríguez V; Domínguez Morales RB; Pérez Cristiá RB
    Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current development in regulation of similar biotherapeutic products in Brazil.
    Castanheira LG; Barbano DB; Rech N
    Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards regulation of similar biotherapeutic products: Thailand's perspective.
    Thanaphollert P; Tungsanga K
    Biologicals; 2011 Sep; 39(5):346-7. PubMed ID: 21917474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.